Bambusa's BBT001 shows early promise in atopic dermatitis
July 28, 2026 | 14:39
Bambusa Therapeutics reported preliminary proof-of-concept results showing BBT001 delivered statistically significant improvement in EASI scores beginning at week one for atopic dermatitis patients, with responses continuing to improve over time.
Mobile Version